Press Releases Johnson & Johnson Santiago S.E.

Equities

JNJCL

US4781601046

End-of-day quote Santiago S.E. Other stock markets 03:30:00 04/06/2024 am IST			5-day change	1st Jan Change
1,55,930 ^CLP	0.00%		0.00%	+14.33%

10:07am	J&J: applies to FDA for expanded indication for Prezcobix	CF
04/06	Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	04:59pm	AQ
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	05/06	BU
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	04/06	PU
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	04/06	AQ
Johnson & Johnson Completes Acquisition of Shockwave Medical	03/06	AQ
Johnson & Johnson - First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration	03/06	AQ
Johnson & Johnson Executive Vice President, William N. Hait, M.D., Ph.D., to Retire, Effective September 2024	31/05	AQ
Johnson & Johnson Completes Acquisition of Shockwave Medical	31/05	BU
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Press Release	30/05	PU
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	29/05	AQ
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Transcript	29/05	PU
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	28/05	AQ
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis	28/05	BU
Johnson & Johnson: Meet a nurse who leads clinical trials to find innovative cancer therapies	24/05	AQ
Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA	24/05	PU
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	22/05	BU
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	22/05	AQ
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission	21/05	AQ
Novel biologic could offer ulcerative colitis symptomatic remission	21/05	AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	21/05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST